Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Public ClinicalTrials.gov record NCT03713684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with oral antidiabetic drugs (OADs). Secondary Objectives: * To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on glycemic control. * To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on body weight. * To evaluate the safety of once weekly injection of efpeglenatide.
Study identification
- NCT ID
- NCT03713684
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 370 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2018 (Actual)
- Primary completion
- Nov 20, 2020 (Actual)
- Completion
- Jan 4, 2021 (Actual)
- Last update posted
- Dec 2, 2021
2018 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400038 | Birmingham | Alabama | 35211 | — |
| Investigational Site Number 8400035 | Chandler | Arizona | 85224 | — |
| Investigational Site Number 8400005 | Glendale | Arizona | 85306 | — |
| Investigational Site Number 8400057 | Huntington Park | California | 90255 | — |
| Investigational Site Number 8400058 | La Jolla | California | 92037 | — |
| Investigational Site Number 8400009 | Los Angeles | California | 90057 | — |
| Investigational Site Number 8400045 | Spring Valley | California | 91978 | — |
| Investigational Site Number 8400040 | Tustin | California | 92780 | — |
| Investigational Site Number 8400026 | Van Nuys | California | 91405 | — |
| Investigational Site Number 8400055 | Orlando | Florida | 32825 | — |
| Investigational Site Number 8400041 | Pembroke Pines | Florida | 33026 | — |
| Investigational Site Number 8400025 | Lawrenceville | Georgia | 30044 | — |
| Investigational Site Number 8400052 | West Des Moines | Iowa | 50265 | — |
| Investigational Site Number 8400044 | Lexington | Kentucky | 40503 | — |
| Investigational Site Number 8400001 | Bridgeton | New Jersey | 08302 | — |
| Investigational Site Number 8400039 | New Windsor | New York | 12553 | — |
| Investigational Site Number 8400036 | Morehead City | North Carolina | 28557 | — |
| Investigational Site Number 8400013 | Maumee | Ohio | 43537 | — |
| Investigational Site Number 8400030 | Dallas | Texas | 75230 | — |
| Investigational Site Number 8400063 | Dallas | Texas | 75390-9302 | — |
| Investigational Site Number 8400043 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 8400037 | Layton | Utah | 84041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03713684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2021 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03713684 live on ClinicalTrials.gov.